Article

Antiglycation Activity of Aucubin In Vitro and in Exogenous Methylglyoxal Injected Rats

Eunsoo Jung 1, Su-Bin Park 2, Woo Kwon Jung 2, Hyung Rae Kim 2 and Junghyun Kim 2,*

1 Laboratory of Toxicology, Research Institute for Veterinary Science and College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea; ozz79@snu.ac.kr
2 Department of Oral Pathology, School of Dentistry, Chonbuk National University, Jeonju 54896, Korea; tnqls309@gmail.com (S.-B.P.); wk Jungjbnu@gmail.com (W.K.J.); rlagudfo31@gmail.com (H.R.K.)
* Correspondence: dvmhyun@jbnu.ac.kr; Tel.: +82-63-270-4032; Fax: +82-63-270-4025

Academic Editors: Chiara Tonelli and Katia Petroni
Received: 5 September 2019; Accepted: 8 October 2019; Published: 10 October 2019

Abstract: Advanced glycation end products (AGEs) is a causative factor of various chronic diseases, including chronic kidney disease and atherosclerosis. AGE inhibitors, such as aminoguanidine and pyridoxamine, have the therapeutic activities for reversing the increase in AGEs burden. This study evaluated the inhibitory effects of aucubin on the formation of methylglyoxal (MGO)-modified AGEs in vitro. We also determined the potential activity of aucubin in reducing the AGEs burden in the kidney, blood vessel, heart, and retina of exogenously MGO-injected rats. Aucubin inhibited the formation of MGO-modified AGE-bovine serum albumin (IC50 = 0.57 ± 0.04 mmol/L) and its cross-links to collagen (IC50 = 0.55 ± 0.02 mmol/L) in a dose-dependent manner. In addition, aucubin directly trapped MGO (IC50 = 0.22 ± 0.01 mmol/L) in vitro. In exogenous MGO-injected rats, aucubin suppressed the formation of circulating AGEs and its accumulation in various tissues. These activities of aucubin on the MGO-derived AGEs in vitro and in vivo showed its pharmacological potential for inhibiting AGEs-related various chronic diseases.

Keywords: advanced glycation end products; aucubin; methylglyoxal

1. Introduction

The advanced glycation end products (AGEs) are generated in the human body and affect the structure and function of proteins. This process was first introduced by Louis-Camille Maillard in 1912 [1]. The glycation process leads to loss of protein function and impaired tissue elasticity [2–4]. AGEs are slowly formed during the process of aging, and some conditions such as diabetes and tissue oxidative stress accelerate this process [5,6]. AGEs are naturally formed in trace amounts in the body by protein or lipid glycation with sugars, and most of them are catabolized depending on the state or type of antioxidative systems, in respective tissues, macromolecular turnover, receptor-mediated degradation, and renal elimination [7]. However, a chronic increase in intracellular oxidative stress accelerates the formation of AGEs and leads to their accumulation in the intracellular space. Oxidative stress is further fueled by excessive reactive oxygen stress (ROS) generation from glucose autoxidation and also the nonenzymatic, covalent attachment of glucose molecules to circulating proteins that result in the formation of AGEs [8–10]. The formation of AGEs is an irreversible reaction and AGEs can form cross-links with proteins resulting in disturbed biochemical reactions, thus AGEs are implicated in pathogenic processes of various age-related diseases [11]. Particularly, matrix proteins such as collagen are properly cross-linked with AGEs in conditions like diabetes and aging [12,13].

Methylglyoxal (MGO) is known as a major precursor of AGEs and is generated as a by-product of glycolysis. MGO easily forms AGEs due to its high reactivity which allows it to cross-link with proteins [14]. MGO-derived protein modifications have been shown in human tissues [15]. Previous
studies have shown that AGEs play an important role in pathogenic processes involved in chronic kidney disease (CKD) [16], Alzheimer’s disease [17], and diabetic complications [18].

Some natural and synthetic compounds have been considered to be AGE inhibitors [19]. *Aucuba japonica* Thunb. is a traditional Korean medicinal herb and has been used to treat several diseases, such as edema and inflammation [20]. Aucubin is an iridoid glucoside isolated from this plant and has various pharmacological activities, such as antioxidant, anti-inflammatory, antimicrobial, antianalgesic, and antitumor effects [21–23]. Despite the various effects of *A. japonica* and its bioactive ingredient aucubin, it remains unclear whether aucubin has inhibitory effects on the glycation processes and its cross-links with proteins. Therefore, the aim of this study was to evaluate the inhibitory effect of aucubin on the formation of MGO-derived AGEs in vitro; furthermore, aucubin was used in exogenous MGO-injected rats to verify its preventive effect on the accumulation of AGEs in vivo.

2. Results

2.1. Inhibitory Activity of Aucubin on MGO-Derived AGEs Formation In Vitro

As shown in Figure 1, aucubin exhibited inhibitory activity on the formation of MGO-derived AGE (IC50 = 0.57 ± 0.04 mmol/L), its inhibitory activity was 5-times stronger than AG (IC50 = 2.69 ± 0.06 mmol/L).

![Inhibitory effect of aucubin and AG on the formation of methylglyoxal (MGO)-derived advanced glycation end products (AGEs) in vitro. All results are expressed as the mean ± SE, n = 4. The IC50 values were determined from the plotted graph.](image)

**Figure 1.** Inhibitory effect of aucubin and AG on the formation of methylglyoxal (MGO)-derived advanced glycation end products (AGEs) in vitro. All results are expressed as the mean ± SE, n = 4. The IC50 values were determined from the plotted graph.

2.2. Inhibitory Activity of Aucubin on AGEs Cross-Linking with Rat Tail Tendon Collagen

The inhibition of AGE-BSA cross-linking to collagen at various concentrations of aucubin was tested. As shown in Figure 2, aucubin inhibited dose-dependently the cross-linking of AGE-modified BSA with collagen (IC50 = 0.55 ± 0.02 mmol/L) and has a 48-times stronger antiglycation activity than AG (IC50 = 26.40 ± 1.20 mmol/L).
2.4. Effect of Aucubin on AGEs Formation in Exogenous MGO-Injected Rats

In order to determine whether intraperitoneal injection of exogenous MGO accelerates the formation of MGO-derived AGEs, we measured the circulating levels of AGEs in the blood. At the end of the study, AGEs were rarely found in the control group, but higher levels of those were found in the MGO-injected rats. However, the treatment of aucubin dose-dependently inhibited the formation of AGEs compared to the MGO group. Treatment with a high dose of aucubin (25 mg/kg) showed similar efficacy of inhibition as that shown by treatment with AG (50 mg/kg) (Figure 4).
2.5. Effect of Aucubin on AGEs Accumulations in Exogenous MGO-Injected Rats

We next determined whether the AGEs are accumulated in various tissues of the MGO-injected rats. Hence, the immunohistochemical staining of AGEs was performed. As shown in Figure 5, AGE was almost undetectable in the control group, but higher levels of those were found in kidney, blood vessel, heart, and retina of MGO injected rats. However, the treatment of aucubin dose-dependently inhibited the tissue accumulation of AGEs compared to the MGO group.

Figure 4. Circulating AGEs formation in the blood of exogenous MGO-injected rats. NOR, normal control rats; MGO, exogenous MGO-injected rats; AG, MGO treated with aminoguanidine (50 mg/kg); Aucubin-10, MGO treated with aucubin (10 mg/kg); Aucubin-25, MGO treated with aucubin (25 mg/kg). All data are expressed the mean ± SE, n = 6.

Figure 5. Cont.
This study reveals that aucubin exhibits the breaking ability of MGO. Aminoguanidine’s anti-AGE activity involves its ability to act as a scavenger of highly reactive dicarbonyls [33]. Aminoguanidine reacts with methylglyoxal to form carbonyls. Other AGE inhibitors, including 2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) and pyridoxamine, also inhibit formation of AGEs through interaction with reactive carbonyls such as MGO scavengers [32]. This study reveals that aucubin exhibits the breaking ability of MGO. Aminoguanidine’s anti-AGE activity involves its ability to act as a scavenger of highly reactive dicarbonyls [33]. Aminoguanidine reacts with methylglyoxal to form triazine adducts [34]. Aucubin is one of the iridoid glucosides. When compared to aminoguanidine, iridoids do not form triazine adducts, as they contain no nitrogen [35]. The antiglycation action of iridoids may even involve different Maillard products. The exact mechanism of action still requires further investigation. Collectively, these results suggest that the MGO breaking activity shown by aucubin might contribute to the inhibition of both the formation and accumulation of AGEs in various tissues and might inhibit the development of AGEs-related diseases.

In order to verify the antiglycation activity of aucubin in vivo, aucubin was administered orally to rats injected with exogenous MGO. In the MGO-injected rats, AGEs were highly generated in blood and accumulated in various tissues. AGEs are considered to play an important role in major pathogenic processes like age-related renal failure, atherosclerosis, and diabetic retinopathy [13,16,18,36,37]. In this study, aucubin prevented the formation of circulating AGEs in the blood of rats injected intraperitoneally.
with exogenous MGO. In addition, aucubin ameliorated the accumulation of AGEs in various tissues in these rats. Many studies have demonstrated the effects of aucubin against diabetes-induced pancreas injury [38] and carbon tetrachloride-induced hepatic damage [39] through its antioxidant action in various experimental models. MGO has been shown to induce ROS generation [40]. AGEs also act as a source of generation of ROS [13]. In our in vitro system, the IC$_{50}$ dose of aucubin to the glycation process was as low as 20 $\mu$mol/L. Aucubin was also effective in vivo at a dose of 25 mg/kg. Xu et al. reported that the peak plasma concentration of aucubin following the oral consumption of 50 mg/kg aucubin in male SD rats was 11.6 $\mu$mol/L at a concentration peak time of 1.08 h [41]. Based on previous reports and our results, our finding regarding the effective dose of aucubin in vitro is consistent with the in vivo results. Although aucubin has shown multiple pharmacological effects, no information is available about the toxicology of aucubin. Shen et al. showed that the intraperitoneal injection of 40 mg/kg aucubin produced no toxic and adverse effects in mice [42]. Taken together, these results indicate that aucubin is able to prevent AGEs burden in various tissues by its ability to act as a breaking agent for MGO.

In conclusion, our results suggest that aucubin could be considered as a prospective candidate for preventative treatment for pathogenic processes of various chronic diseases associated with the accumulation of AGES.

4. Materials and Methods

4.1. In Vitro Assay of the Formation of MGO-Derived AGEs

Bovine serum albumin (BSA, 10 mg/mL, Sigma Chemicals, St. Louis, MO, USA) was incubated at 4 $^\circ$C for 1 week with 5 mmol/L MGO in sodium phosphate buffer (0.1 M, pH 7.4). Aucubin (Sigma Chemicals, MO, USA) and aminoguanidine (Sigma Chemicals, MO, USA) were added in this reaction mixture. The levels of MGO-derived AGEs were calculated by measuring the fluorescence intensity using a spectrofluorometer (excitation wavelength at 370 nm and emission wavelength at 440 nm). The IC$_{50}$ concentration was calculated.

4.2. In Vitro Assay of the Cross-Linking of Glycated Proteins

AGE-modified BSA (1 $\mu$g, TransGenic Inc, Kobe, Japan) was treated with or without aucubin or AG, respectively, in collagen-coated 96-well plates and incubated for 4 h. The collagen-AGE-BSA cross-linked complex was detected using a horseradish peroxidase-linked mouse anti-AGE antibody (6D12, Wako, Osaka, Japan). The IC$_{50}$ concentration was calculated.

4.3. MGO Assay

MGO (0.05 mmol/L, Sigma, MO, USA) was treated with or without aucubin or AG for 30 min. After incubation, o-phenylene diamine (derivatization agent, 10 mmol/L) was added to each sample, and the mixtures were kept at room temperature for 30 min for derivatization of the remaining MGO. Levels of remaining MGO were then measured as previously described [43].

4.4. Animals and Experimental Design

All procedures involving the use of animals were approved by the Institutional Animal Care and Use Committee (IACUC approval No. 2019-17). Sprague–Dawley (SD) rats (~200 g) were randomized into five groups of 6 rats each. Group 1: normal rat (NOR); Group 2: rats treated with MGO using an intraperitoneal (i.p.) injection (MGO); Group 3: rats treated with MGO using an i.p. injection and orally administered 50 mg/kg of AG (AG); Group 4: ~5 rats treated with MGO using an i.p. injection and orally administered two different doses of 10 and 25 mg/kg of aucubin once a day for 2 weeks. We selected the i.p. route to achieve a pathologically relevant plasma concentration of 2–5 mmol/L MGO [44,45]. Following the protocol from a previous report [46], we administered 17.25 mg/kg (240 mmol/kg) of MGO using a single i.p. injection.
4.5. Quantification of Serum AGE Levels

At necropsy, blood was collected and serum AGE levels were calculated using an AGE ELISA kit (MyBioSource Inc, San Diego, CA, USA) according to the manufacturer’s instruction.

4.6. Immunohistochemical Staining

At necropsy, the kidney, blood vessel, heart, and retina were fixed with 10% (v/v) formaldehyde and embedded in paraffin, and 5-µm-thick sections were prepared. Immunohistochemical staining was performed for AGEs using a monoclonal mouse anti-AGE antibody (6D12, Wako, Osaka, Japan) according to a previously reported method [47]. Briefly, deparaffinized sections were hydrated and treated with 1% H₂O₂ in methanol prior to incubation with primary antibodies for 1 h at room temperature. Signals for AGEs were detected using the Envision kit (DAKO, Carpinteria, CA, USA) and visualized using a DAB peroxidase substrate kit (Vector Labs, Burlingame, CA, USA). As a negative control, tissue sections were incubated with serum from nonimmunized animals, instead of the primary antibody. The intensity of positively stained areas was determined from five randomly selected areas at 100x magnification using the ImageJ software (National Institutes of Health, Bethesda, MD, USA).

4.7. Statistical Analysis

All data were expressed as the mean ± standard error of the mean (SE). Differences between groups were determined by one-way ANOVA followed by Tukey’s post-hoc test using Prism 6.0 (GraphPad, La Jolla, CA, USA).

Author Contributions: E.J. performed the experiments and wrote the manuscript; S.-B.P., W.K.J., and H.R.K. performed the experiments and analyzed the data; J.K. designed and supervised the study. All authors read and approved the final manuscript.

Funding: This research was supported by the R&D Program for Forest Science Technology (Project No. 2017040A00-1719-BA01) provided by the Korea Forest Service (Korea Forestry Promotion Institute). Part of this study was carried out with the support of the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. NRF-2019R1A2C1008773).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Maillard, L. Action des acides amines sur les sucres; formation des melanoidines par voie methodique. C. R. Acad. Sci. 1912, 154, 66–68.
2. Sell, D.R.; Monnier, V.M. Molecular basis of arterial stiffening: Role of glycation—A mini-review. Gerontology 2012, 58, 227–237. [CrossRef]
3. Semba, R.D.; Nicklett, E.J.; Ferrucci, L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65, 963–975. [CrossRef] [PubMed]
4. Nguyen, H.P.; Katta, R. Sugar Sag: Glycation and the Role of Diet in Aging Skin. Skin Ther. Lett. 2015, 20, 1–5.
5. Lopez-Clavijo, A.F.; Duque-Daza, C.A.; Soulby, A.; Canelon, I.R.; Barrow, M.; O’Connor, P.B. Unexpected crosslinking and diglycation as advanced glycation end-products from glyoxal. J. Am. Soc. Mass Spectrom. 2014, 25, 2125–2133. [CrossRef] [PubMed]
6. Ahmed, N.; Thornalley, P.J. Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem. Soc. Trans. 2003, 31, 1417–1422. [CrossRef]
7. Vlassara, H.; Urribarri, J. Advanced glycation end products (AGE) and diabetes: Cause, effect, or both? Curr. Diabetes Rep. 2014, 14, 453. [CrossRef]
8. Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. Circ. Res. 2010, 107, 1058–1070. [CrossRef]
9. Bakala, H.; Ladouce, R.; Baraibar, M.A.; Friguet, B. Differential expression and glycative damage affect specific mitochondrial proteins with aging in rat liver. Biochim. Biophys. Acta 2013, 1832, 2057–2067. [CrossRef]
10. Wu, L.; Juurlink, B.H. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. *Hypertension* **2002**, *39*, 809–814. [CrossRef]

11. Brownlee, M. Advanced glycation in diabetes and aging. *Annu. Rev. Med.* **1995**, *46*, 223–234. [CrossRef] [PubMed]

12. Kim, J.; Jeong, I.H.; Kim, C.S.; Lee, Y.M.; Kim, J.M.; Kim, J.S. Chlorogenic acid inhibits the formation of advanced glycation end products and associated protein cross-linking. *Arch. Pharm. Res.* **2011**, *34*, 495–500. [CrossRef] [PubMed]

13. Stitt, A.W. The role of advanced glycation in the pathogenesis of diabetic retinopathy. *Exp. Mol. Pathol.* **2003**, *75*, 95–108. [CrossRef]

14. Bourrajaj, M.; Stehouwer, C.D.; van Hinsbergh, V.W.; Schalkwijk, C.G. Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. *Biochem. Soc. Trans.* **2003**, *31*, 1400–1402. [CrossRef] [PubMed]

15. Shamsi, F.A.; Partal, A.; Sady, C.; Glomb, M.A.; Nagaraj, R.H. Immunological evidence for methylglyoxal-derived modifications in vivo. Determination of antigenic epitopes. *J. Biol. Chem.* **1998**, *273*, 6928–6936. [CrossRef] [PubMed]

16. Agalou, S.; Ahmed, N.; Babaei-Jadidi, R.; Dawnay, A.; Thornalley, P.J. Profound mishandling of protein glycation degradation products in uremia and dialysis. *J. Am. Soc. Nephrol.* **2005**, *16*, 1471–1485. [CrossRef] [PubMed]

17. Taniguchi, N.; Takahashi, M.; Kizuka, Y.; Kitazume, S.; Shuvaev, V.V.; Ookawara, T.; Furuta, A. Glycation vs. glycosylation: A tale of two different chemistries and biology in Alzheimer’s disease. *Glycoconj. J.* **2016**, *33*, 487–497. [CrossRef] [PubMed]

18. Kalia, K.; Sharma, S.; Mistry, K. Non-enzymatic glycosylation of immunoglobulins in diabetic nephropathy. *Clin. Chim. Acta* **2004**, *347*, 169–176. [CrossRef] [PubMed]

19. Osawa, T.; Kato, Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. *Ann. N. Y. Acad. Sci.* **2005**, *1043*, 440–451. [CrossRef]

20. Kimura, T.; But, P.P.H.; Guo, J.X.; Sung, C.K. *International Collation of Traditional and Folk Medicine*; World Scientific: Singapore, 1997; Volume 2.

21. Park, K.S.; Chang, I.-M. Anti-inflammatory activity of aucubin by inhibition of tumor necrosis factor-α production in RAW 264.7 cells. *Planta Med.* **2004**, *70*, 778–779. [CrossRef] [PubMed]

22. Xue, H.Y.; Gao, G.Z.; Lin, Q.Y.; Jin, L.J.; Xu, Y.P. Protective effects of aucubin on H2O2-induced apoptosis in PC12 cells. *Phytother. Res.* **2012**, *26*, 369–374. [CrossRef] [PubMed]

23. Hung, J.Y.; Yang, C.J.; Tsai, Y.M.; Huang, H.W.; Huang, M.S. Antiproliferative activity of aucubin is through cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells. *Clin. Exp. Pharmacol. Physiol.* **2008**, *35*, 995–1001. [CrossRef] [PubMed]

24. Tan, K.C.; Chow, W.S.; Lam, J.C.; Lam, B.; Bucala, R.; Betteridge, J.; Ip, M.S. Advanced glycation endproducts in nondiabetic patients with obstructive sleep apnea. *Sleep* **2006**, *29*, 329–333. [CrossRef] [PubMed]

25. Srikanth, V.; Maczurek, A.; Phan, T.; Steele, M.; Westcott, B.; Juskiw, D.; Munch, G. Advanced glycation endproducts and their receptor RAGE in Alzheimer’s disease. *Neurobiol. Aging* **2011**, *32*, 763–777. [CrossRef] [PubMed]

26. Simm, A.; Wagner, J.; Gursinsky, T.; Nass, N.; Friedrich, I.; Schinzel, R.; Czeslik, E.; Silber, R.E.; Scheuibel, R.J. Advanced glycation endproducts: A biomarker for age as an outcome predictor after cardiac surgery? *Exp. Gerontol.* **2007**, *42*, 668–675. [CrossRef] [PubMed]

27. Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. *Diabetes* **2005**, *54*, 1615–1625. [CrossRef] [PubMed]

28. Thornalley, P.J.; Langborg, A.; Minhas, H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. *Biochem. J.* **1999**, *344*, 109–116. [CrossRef]

29. Stopper, H.; Schinzel, R.; Sebekova, K.; Heidland, A. Genotoxicity of advanced glycation end products in mammalian cells. *Cancer Lett.* **2003**, *190*, 151–156. [CrossRef]

30. Pokupec, R.; Kalauz, M.; Turk, N.; Turk, Z. Advanced glycation endproducts in human diabetic and non-diabetic cataractous lenses. *Graefes Arch. Clin. Exp. Ophthalmol.* **2003**, *341*, 378–384. [CrossRef]

31. Mesias, M.; Navarro, M.; Gokmen, V.; Morales, F.J. Antiglycative effect of fruit and vegetable seed extracts: Inhibition of AGE formation and carbonyl-trapping abilities. *J. Sci. Food Agric.* **2013**, *93*, 2037–2044. [CrossRef]
32. Nagaraj, R.H.; Sarkar, P.; Mally, A.; Biemel, K.M.; Lederer, M.O.; Padayatti, P.S. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: Characterization of a major product from the reaction of pyridoxamine and methylglyoxal. *Arch. Biochem. Biophys.* 2002, 402, 110–119. [CrossRef]

33. Thornalley, P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. *Arch. Biochem. Biophys.* 2003, 419, 31–40. [CrossRef] [PubMed]

34. Thornalley, P.J.; Yurek-George, A.; Argirov, O.K. Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucose under physiological conditions. *Biochem. Pharmacol.* 2000, 60, 55–65. [CrossRef]

35. West, B.J.; Uwaya, A.; Isami, F.; Deng, S.; Nakajima, S.; Jensen, C.J. Antiglycation Activity of Iridoids and Their Food Sources. *Int. J. Food Sci.* 2014, 2014, 276950. [CrossRef] [PubMed]

36. Park, S.; Kim, C.S.; Min, J.; Lee, S.H.; Jung, Y.S. A high-fat diet increases oxidative renal injury and protein glycation in D-galactose-induced aging rats and its prevention by Korea red ginseng. *J. Nutr. Sci. Vitaminol. (Tokyo)* 2014, 60, 159–166. [CrossRef] [PubMed]

37. Del Turco, S.; Basta, G. An update on advanced glycation endproducts and atherosclerosis. *Biofactors* 2012, 38, 266–274. [CrossRef] [PubMed]

38. Jin, L.; Xue, H.-Y.; Jin, L.-J.; Li, S.-Y.; Xu, Y.-P. Antioxidant and pancreas-protective effect of aucubin on rats with streptozotocin-induced diabetes. *Eur. J. Pharmacol.* 2008, 582, 162–167. [CrossRef] [PubMed]

39. Chang, I.-M. Liver-protective activities of aucubin derived from traditional oriental medicine. *Res. Commun. Mol. Pathol. Pharmacol.* 1998, 102, 189–204.

40. Miyazawa, N.; Abe, M.; Souma, T.; Tanemoto, M.; Abe, T.; Nakayama, M.; Ito, S. Methylglyoxal augments intracellular oxidative stress in human aortic endothelial cells. *Free Radic. Res.* 2010, 44, 101–107. [CrossRef]

41. Xu, W.; Deng, Z.; Guo, H.; Ling, P. A rapid and sensitive determination of aucubin in rat plasma by liquid chromatography–tandem mass spectrometry and its pharmacokinetic application. *Biomed. Chromatogr.* 2012, 26, 1066–1070. [CrossRef]

42. Shen, B.; Zhao, C.; Wang, Y.; Peng, Y.; Cheng, J.; Li, Z.; Wu, L.; Jin, M.; Feng, H. Aucubin inhibited lipid accumulation and oxidative stress via Nrf2/HO-1 and AMPK signalling pathways. *J. Cell. Mol. Med.* 2019, 23, 4063–4075. [CrossRef] [PubMed]

43. Kim, J.H.; Kim, M.I.; Syed, A.S.; Jung, K.; Kim, C.Y. Rapid Identification of Methylglyoxal Trapping Constituents from Onion Peels by Pre-column Incubation Method. *Nat. Prod. Sci.* 2017, 23, 247–252. [CrossRef]

44. McLellan, A.C.; Thornalley, P.J.; Benn, J.; Sonksen, P.H. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. *Clin. Sci.* 1994, 87, 21–29. [CrossRef] [PubMed]

45. Wang, H.; Meng, Q.H.; Gordon, J.R.; Khandwala, H.; Wu, L. Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. *Clin. Biochem.* 2007, 40, 1232–1239. [CrossRef] [PubMed]

46. Dhar, A.; Desai, K.M.; Wu, L. Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats. *Br. J. Pharmacol.* 2010, 159, 166–175. [CrossRef] [PubMed]

47. Jung, E.; Kim, J.; Ho Kim, S.; Kim, S.; Cho, M.H. Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy. *Eur. J. Pharmacol.* 2015, 761, 116–124. [CrossRef] [PubMed]

**Sample Availability:** Samples of the compounds at amounts less than 1 mg are available from the authors.

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).